Skip to main content

Heron Therapeutics Value Stock - Dividend - Research Selection

Heron Therapeutics

ISIN: US4277461020, WKN: A1XB6K

Market price date: 22.01.2021
Market price: 17,71 USD

Heron Therapeutics Fundamental data and company key figures of the share

Annual reports in USD
Key figures 05-03-2020
Cash flow
Net operating cash flow -124.580.000
Capital Expenditures -7.154.000
Free cash flow -131.734.000
Balance sheet
Total Equity 403.835.000
Liabilities & Shareholders equity 512.782.000
Income statement
Net income -204.749.000
Eps (diluted) -2,500
Diluted shares outstanding 81.899.600
Net sales/revenue 145.970.000

Fundamental ratios calculated on: 22-01-2021

Key figures 22-01-2021
Cash flow
P/C -11,64
P/FC -11,01
Balance sheet
Income statement
Div. Yield0,00%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization1.450.441.856,00 USD
CountryUnited States
IndicesNASDAQ Comp.
Raw Data SourceUS GAAP in Millionen USD
Stock Split2014-01-13,1.0000/20.0000; 2007-05-25,1.0000/4.0000

Description of the company

Heron Therapeutics, Inc., a biotechnology company, engages in developing medicines to address unmet medical needs. The company\'s product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron) extended-release injection for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens. The company is also developing CINVANTI, a neurokinin-1 receptor antagonist aprepitant for the prevention of CINV; and HTX-011, which is in Phase III clinical development for the prevention of post-operative pain. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,